MetaCap

X4 Pharmaceuticals Insider Trades

NASDAQ: XFORHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

2.91+0.115 (+4.11%)

Market open · Delayed 15 min · as of Oct 9, 1:58 PM ET

Last 12 months

Purchases
1 · $250.00K
Sales
5 · $462.96K
Shares bought / sold
86.21K / 109.28K
Net activity
Net selling $212,967

X4 Pharmaceuticals insider activity

Over the last 12 months, X4 Pharmaceuticals insiders reported 6 transactions on SEC Form 4: 1 open-market purchase and 5 sales. Insiders bought $249,997 and sold $462,964 worth of stock, for net insider selling of $212,967. The largest seller was Craig Adam R, with $210,829 in reported sales.

The most recent filing shows KIRSKE DAVID (Chief Financial Officer) selling 11,767 shares at $2.86 on Oct 1, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put XFOR's ownership changes in context.

Summary generated from market data by MetaCap's automated system. Methodology

XFOR insider transactions

X4 Pharmaceuticals insider transactions
DateInsiderTypeSharesValueFiling
Oct 1, 2026KIRSKE DAVIDChief Financial OfficerSale11,767$33.66KForm 4
Aug 12, 2026Craig Adam RExecutive ChairmanSale47,436$210.83KForm 4
Aug 12, 2026Volpone JohnPresidentSale24,576$109.23KForm 4
Jun 30, 2026KIRSKE DAVIDChief Financial OfficerSale8,543$36.43KForm 4
May 12, 2026KIRSKE DAVIDChief Financial OfficerSale16,961$72.82KForm 4
Oct 23, 2025Craig Adam RExecutive ChairmanBuy86,206$250.00KForm 4
Aug 14, 2025KIRSKE DAVIDChief Financial OfficerAward193,254—Form 4
Aug 14, 2025Craig Adam RExecutive ChairmanAward289,881—Form 4
Aug 14, 2025Volpone JohnPresidentAward289,881—Form 4
Jun 9, 2025WYZGA MICHAEL SDirectorAward1,500—Form 4
Jun 9, 2025MCGIRR DAVID W JDirectorAward1,500—Form 4
Jun 9, 2025Woods KeithDirectorAward1,500—Form 4
Jun 9, 2025Bridger GaryDirectorAward1,500—Form 4
Jun 9, 2025Stewart MurrayDirectorAward1,500—Form 4
Jun 9, 2025de Craecker FrancoiseDirectorAward1,500—Form 4
May 20, 2025Thoren Natasha FayChief Legal OfficerAward3,333—Form 4
May 16, 2025Baldry MarkChief Commercial OfficerBuy1,032$2.56KForm 4
May 16, 2025Baldry MarkChief Commercial OfficerAward1,032$2.56KForm 4
Feb 12, 2025Ragan PaulaPresident and CEOAward2,250,000—Form 4
Feb 12, 2025Mostafa Adam S.Chief Financial OfficerAward850,000—Form 4
Feb 12, 2025Arbet-Engels ChristopheChief Medical OfficerAward850,000—Form 4
Feb 12, 2025DiBiase MaryChief Operating OfficerAward650,000—Form 4
Feb 12, 2025Baldry MarkChief Commercial OfficerAward600,000—Form 4
Jan 24, 2025Arbet-Engels ChristopheChief Medical OfficerSale11,624$5.28KForm 4
Jan 24, 2025DiBiase MaryChief Operating OfficerSale22,258$10.09KForm 4
Jan 24, 2025Baldry MarkChief Commercial OfficerSale29,159$13.24KForm 4
Jan 24, 2025Ragan PaulaPresident and CEOSale76,473$34.72KForm 4
Jan 24, 2025Mostafa Adam S.Chief Financial OfficerSale74,773$33.95KForm 4
Jan 23, 2025Arbet-Engels ChristopheChief Medical OfficerAward25,831—Form 4
Jan 23, 2025DiBiase MaryChief Operating OfficerAward61,178—Form 4
Jan 23, 2025Baldry MarkChief Commercial OfficerAward74,773—Form 4
Jan 23, 2025Ragan PaulaPresident and CEOAward169,940—Form 4
Jan 23, 2025Mostafa Adam S.Chief Financial OfficerAward74,773—Form 4
Nov 15, 2024Ragan PaulaPresident and CEOSale31,897$12.58KForm 4
Nov 15, 2024Baldry MarkChief Commercial OfficerBuy13,404$4.60KForm 4
Oct 15, 2024Ragan PaulaPresident and CEOSale31,897$17.93KForm 4
Oct 7, 2024Baldry MarkChief Commercial OfficerSale11,127$6.51KForm 4
Oct 7, 2024Mostafa Adam S.Chief Financial OfficerSale230,645$126.90KForm 4
Oct 4, 2024Baldry MarkChief Commercial OfficerAward34,946—Form 4
Oct 4, 2024Mostafa Adam S.Chief Financial OfficerAward230,645—Form 4
May 17, 2024Baldry MarkChief Commercial OfficerBuy21,646$14.65KForm 4

Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4

Related